A randomized, double-blind, controlled study to evaluate the efficacy and safety of the combination ABT-450 / ritonavir / ABT-267 (ABT-450 / r / ABT267) and ABT-333 with and without ribavirin (RBV) in adults with chronic infection with Hepatitis C virus genotype 1b, not previously treated (PEARL-III)
Abbott GmbH & Co. KG// AbbVie Farmaceutica, S.L.U.
Pathology and candidate patients
Dr. Moises Diago
Hospital Quirónsalud Valencia.
ABT-450 / ritonavir / ABT-267 (ABT-450 / r / ABT267) and ABT-333 with and without ribavirin
April 2, 2013
Hospital Quirónsalud valencia
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the cardiology team by sending an email to the address: firstname.lastname@example.org